Evidence map›Paper›PMID 36229988›Full record

ReviewESC heart failure2023

A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction.

Amr Abdin, Johann Bauersachs, Samira Soltani, Matthias Eden, Norbert Frey, Michael Böhm

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Amr AbdinDepartment of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Center, Saarland University, Saarbrücken, Germany.
Johann BauersachsDepartment of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Samira SoltaniDepartment of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
Matthias EdenDepartment of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
Norbert FreyDepartment of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
Michael BöhmDepartment of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Center, Saarland University, Saarbrücken, Germany.
Heidelberg University · DEMedizinische Hochschule Hannover · DESaarland University · DE

Funding

Projekt DEAL
6 · The paper itself

Abstract

Over the last 15-20 years, remarkable developments of heart failure (HF) pharmacotherapies have been achieved. However, HF remains a global healthcare challenge with more than 64 million patients worldwide. Optimization of guideline-directed chronic HF medical therapy is highly recommended with every patient visit to improve outcomes in patients with HF with reduced ejection fraction. However, the majority of patients in real-world settings are treated with doses that are lower than those with proven efficacy in clinical trials, which might be due to concerns of adverse effects and inertia of physicians. Likewise, a significant proportion of patients still do not receive all drug classes that could improve their prognosis. The recent European Society of Cardiology guidelines do not provide detailed recommendations on how these drug classes should be implemented in the treatment of inpatients to allow for both safety and a high likelihood of efficacy. We therefore propose a practical approach algorithm to support physicians to treat HF patients in their daily practice.

Indexed as

CardiologyHeart FailureAngiotensin Receptor AntagonistsHumansPrognosisStroke VolumeAngiotensin Receptor AntagonistsAlgorithmHeart failureOutcomesTherapy

Identifiers

PMID36229988
PMCPMC9871719
OpenAlexW4306157908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.